Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad is supporting efforts to promote better nutrition among schoolchildren for the second year running. Through the CHAMPS® Nutribar range, the Company’s leading nutrition brand CHAMPS® is the main sponsor of the nationwide Kempen Pemakanan Seimbang CHAMPS® targeted at primary school students.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad (“Duopharma Biotech” or “the Company”) announced profit before tax of RM21.47 million in the second quarter of 2022, an increase of 6.3% from the previous corresponding quarter due to improved sales in the ethical classic segment and public health sector during the period.
Duopharma Biotech Berhad recorded cumulative revenue of RM482.24 million for the first half of FY2026 ended 30 June 2026, which saw the Group’s Profit Before Tax growing 32.1% year-on-year to RM79.71 million, while Profit After Tax rose 32.2% to RM60.59 million, compared to the corresponding period in the preceding year.
Duopharma Biotech Berhad officially launched the Flavettes Merdeka 2026 campaign today, themed ‘Flavettes Setia Menemani Setiap Generasi’ and featuring a multi-prong collaboration with Tourism Malaysia, Watsons Malaysia and Kapten Batik.
Biocon Limited, an innovation-led global biopharmaceutical company, announced that its long-standing partner, Duopharma Biotech Berhad via its wholly-owned subsidiary Duopharma (M) Sendirian Berhad, has secured multiple insulin contracts from the Ministry of Health, Malaysia, valued at over MYR 225 million this year.
Duopharma Biotech Berhad held its 25th Annual General Meeting today, capping a successful FY2025 ended 31 December 2025, that saw the Company growing its revenue by 14.5% to RM931.69 million, from RM813.70 million in FY2024.
Duopharma Biotech Berhad recorded resilient financial performance in the first quarter ended 31 March 2026, delivering a stronger Profit Before Tax (“PBT”) of RM 40.41 million, and Profit After Tax (“PAT”) of RM30.71 million, increasing 19.8% year-on-year, despite Q1FY2026 revenue of RM247.88 million dropping 5.7% compared to RM262.74 million in the same period last year.
Duopharma Biotech Berhad reported a revenue of RM931.69 million for the year ended 31 December 2025, up 14.5% compared to revenue of RM813.70 million in financial year 2024.
